Pharsight

Prialt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653033 TERSERA Method for administering omega-conopeptide
Oct, 2024

(1 year, 1 day from now)

US8765680 TERSERA Method for administering omega-conopeptide
Oct, 2024

(1 year, 1 day from now)

US9707270 TERSERA Method for administering ω-conopeptide
Oct, 2024

(1 year, 1 day from now)

Prialt is owned by Tersera.

Prialt contains Ziconotide Acetate.

Prialt has a total of 3 drug patents out of which 0 drug patents have expired.

Prialt was authorised for market use on 28 December, 2004.

Prialt is available in injectable;intrathecal dosage forms.

Prialt can be used as analgesia; treatment of pain, treatment of pain; analgesia, treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine.

The generics of Prialt are possible to be released after 01 October, 2024.

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Market Authorisation Date: 28 December, 2004

Treatment: Analgesia; Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage

PRIALT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic